Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01804829 · ClinicalTrials.gov registry record · Phase 3
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Phase 3 study, sponsored by Biotest Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT01804829 is a Phase 3 study that has completed, run by Biotest Pharmaceuticals Corporation. The registered enrollment target is 80 participants.
The verdict
NCT01804829, a Phase 3 study, has completed, sponsored by Biotest Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
Interventions
- BIOLOGICAL Civacir® 10%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01804829
The ClinicalTrials.gov registry entry for NCT01804829 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotest Pharmaceuticals Corporation, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Civacir® 10% is the first listed.
NCT01804829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01804829 about?
NCT01804829 is a clinical study titled "Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.". The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
What is the current status of trial NCT01804829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2013-06. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01804829?
The interventions under investigation include: Civacir® 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT01804829?
This trial is sponsored by Biotest Pharmaceuticals Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.